Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities. (17th May 2011)

• Record Type: Journal Article
• Authors: Mossello, Enrico; Ballini, Elena; Boncinelli, Marta; Monami, Matteo; Lonetto, Giuseppe; Mello, Anna Maria; Tarantini, Francesca; Baldasseroni, Samuele; Mannucci, Edoardo; Marchionni, Niccolò
• Other Names: Di Pasquale Giovanni Academic Editor.
• Is Part Of: Experimental diabetes research. Volume 2011(2011)
• Publication Date: 2011-05-17
• Subjects: Diabetes -- Research -- Periodicals; Diabetes -- Research; Periodicals; 616.462
• DOI: 10.1155/2011/281674
• Languages: English
• ISSNs: 1687-5214

Abstract

Abstract : Metabolic and neurodegenerative disorders have a growing prevalence in Western countries. Available epidemiologic and neurobiological evidences support the existence of a pathophysiological link between these conditions. Glucagon-like peptide 1 (GLP-1), whose activity is reduced in insulin resistance, has been implicated in central nervous system function, including cognition, synaptic plasticity, and neurogenesis. We review the experimental researches suggesting that GLP-1 dysfunction might be a mediating factor between Type 2 diabetes mellitus (T2DM) and neurodegeneration. Drug treatments enhancing GLP-1 activity hold out hope for treatment and prevention of Alzheimer's disease (AD) and cognitive decline.